Advertisement

Clinical Drug Investigation

, Volume 21, Issue 4, pp 243–255 | Cite as

Clinical Equivalence of a Salmeterol/Fluticasone Propionate Combination Product (50/500μg) Delivered via a Chlorofluorocarbon-Free Metered-Dose Inhaler with the Diskus™ in Patients with Moderate to Severe Asthma

  • J. A. van Noord
  • H. Lill
  • T. Carrillo Diaz
  • A. P. Greefhorst
  • P. Davies
Clinical Use

Abstract

Objective

To demonstrate equivalent efficacy and comparable tolerability of two inhaled combined formulations of salmeterol/fluticasone propionate (SALM/FP) 50/500μg twice daily in asthma patients.

Design and Setting

Multicentre, double-blind, parallel-group study.

Patients

Patients aged 12 to 82 years with moderate to severe asthma who were symptomatic on existing inhaled corticosteroid therapy.

Methods

176 patients were randomised to SALM/FP 50/500μg twice daily via a novel hydrofluoroalkane (HEA) metered-dose inhaler (MDI; 25/250μg per actuation), and 161 received the same dosage of SALM/FP via a dry powder Diskus™ inhaler (50/500μg) for 12 weeks. A third group of patients (n = 172) received the same dosage of steroid, FP 500μg twice daily, alone via a chlorofluorocarbon (CFC) MDI (250μg per actuation). The primary efficacy parameter was change in morning peak expiratory flow (PEF) over weeks 1 to 12.

Results

The SALM/FP MDI was clinically equivalent to the SALM/FP Diskus™ for the mean change in morning PEF over weeks 1 to 12 [adjusted mean increases 50 and 48 L/min, respectively; treatment difference −2 L/min; 95% confidence interval (CI):−11 to 7 L/min]. The SALM/FPMDI produced significantly greater improvements in morning PEF than the FPMDI (difference: −23 L/min; 95% CI: −32 to −14), with superiority for all secondary efficacy measures. All three treatments were well tolerated, with similar profiles and incidences of adverse events.

Conclusions

At a dosage of 50/500μg twice daily, the SALM/FP 25/250μg HFA MDI (two actuations twice daily) is clinically equivalent to the SALM/FP 50/500μg Diskus™ (one actuation twice daily). The availability of two formulations offers patients a choice of delivery systems when switching to combination therapy with SALM/FP.

Keywords

Fluticasone Propionate Salmeterol Peak Expiratory Flow Beclomethasone Dipropionate Morning Peak Expiratory Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank all the investigators who participated in the study: Dr M. de Jonghe, Dr W. Demedts, Dr J. Martinot, Dr D. Rozen, Dr G. Vandermoten (Belgium); Dr H. Lill, Prof. I. Jannus-Prulijan, Dr P. Pullisaar (Estonia); Dr T. Karakorpi, Dr R. Kauppinen, Dr J. Kotaniemi, Dr P. Nieminen (Finland); Prof. M. Aubier, Prof D. Dusser, Dr E. Fournier, Prof. M. Fournier, Dr J-P. Grignet, Dr M. Grosclaude, Dr N. Grunchec, Dr M. Legendre, Dr J-P. Maffre, Dr J. Robert (France); Dr I. Herjavecz, Prof. P. Kraszko, Dr P. Magyar, Dr H. Zibotics (Hungary); Dr L. Clancy, Dr K. Ward (Ireland); Dr A. Grinberga, Prof. V. Sillins (Latvia); Dr R. Sakalauskas, Prof. B. Satkauskas (Lithuania);Prof. P. Carlos, Dr R. Neveda, Dr J. Roldao Vieira (Portugal); Prof. T. Cheng, Dr T. Khim (Singapore); Dr S. Bardagi, Dr T. Carrillo Diaz, Dr L. Fernadez de Corres, Dr J. Garcia, Dr N. Gonzalez, Dr C. Picado (Spain); Dr L. Lazer, Dr H. Matsol, Dr B. Olsson, Dr E. Ostling-Kulling, Dr M. Palmqvist, Dr M. Soderberg, Prof. G. Stalenheim, Dr J. Ziegler (Sweden); Dr C. Apap, Dr J. Creemers, Dr D. de Munck, Dr E. Dubois, Dr W. Evers, Dr A. Greefhorst, Dr C. Hensing, Dr H. Pasma, Dr W. Pieters, Dr W. Strankinga, Dr A. van Harreveld, Dr J. van Noord, Dr J. Westbroek (The Netherlands).

This study was sponsored by Glaxo Wellcome.

Seretide™, Diskus™ and Ventolin™ are trademarks of the Glaxo Wellcome group.

References

  1. 1.
    Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24PubMedCrossRefGoogle Scholar
  2. 2.
    Woolcock A, Lundbäck B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroid with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8PubMedGoogle Scholar
  3. 3.
    Van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54: 207–12CrossRefGoogle Scholar
  4. 4.
    Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999; 20: 173–80PubMedCrossRefGoogle Scholar
  5. 5.
    Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11PubMedCrossRefGoogle Scholar
  6. 6.
    Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–73PubMedCrossRefGoogle Scholar
  7. 7.
    British Thoracic Society. The British guidelines on asthma management 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1–21Google Scholar
  8. 8.
    National Institutes of Health, National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. Expert panel report 2. July 1997. NIH publication no.: 97-4051Google Scholar
  9. 9.
    Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute. November 1998. NIH publication no.: 96-3659BGoogle Scholar
  10. 10.
    Malton A, Sumby BS, Smith IJ. A comparison of in-vitro drug delivery from two multi-dose powder inhalation devices. Eur J Clin Res 1995; 7: 177–93Google Scholar
  11. 11.
    Malton A, Sumby BS, Dandiker Y. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhalers. J Pharm Med 1996; 6: 35–48Google Scholar
  12. 12.
    Johal B, Gibson GJ, Small T, et al. Use of inhalation profiles from patients with severe obstructive lung disease using the Diskus inhaler and Turbuhaler inhaler to evaluate device performance ex vivo. Eur Respir J 1997; 10: 258sGoogle Scholar
  13. 13.
    Conway J, Smith S, Schreiber J, et al. Comparison of peak pressure drops through powder inhalers drug inspiration at maximum flow rate. Am J Respir Crit Care Med 1996; 153: A59Google Scholar
  14. 14.
    Luyt D, Vermeiden J, Johnson L, et al. A comparison of the ease of handling of the Diskus/Accuhaler inhaler and the Turbuhaler inhaler in children aged 6–12 years with asthma. J Aerosol Med 1995; 8: 105Google Scholar
  15. 15.
    Schlaeppi M, Edwards K, Fuller RW, et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract 1996; 50: 14–9PubMedGoogle Scholar
  16. 16.
    Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16: 193–201CrossRefGoogle Scholar
  17. 17.
    Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Ped Pulmonol 2000; 30: 97–105CrossRefGoogle Scholar
  18. 18.
    Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6: 45–51PubMedGoogle Scholar
  19. 19.
    Aubier M, Pieters WR, Schlösser NJJ, et al. Salmeterol/ fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876–4PubMedCrossRefGoogle Scholar
  20. 20.
    Woodcock A. Continuing patient care with metered-dose inhalers. J Aerosol Med 1995; 8 Suppl. 20: S5–10PubMedGoogle Scholar
  21. 21.
    Partridge MR. Metered-dose inhalers and CFCs: what respiratory physicians need to know. Respir Med 1994; 88: 645–7PubMedCrossRefGoogle Scholar
  22. 22.
    Montreal protocol on substances that deplete the ozone layer. ILM 1987 Sept 16; 1541Google Scholar
  23. 23.
    Committee for Proprietary Medicinal Products. The note for guidance on replacement CFCs in metered dose inhalation products. 1993. European Union CPMP guidelines III/5462/93 Rev 1Google Scholar
  24. 24.
    Boulet LP, Cowie R, Johnston P, et al. Comparison of Diskus inhaler, a new multidose powder inhaler with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian study group. J Asthma 1995; 32: 429–36PubMedCrossRefGoogle Scholar
  25. 25.
    Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6 Suppl. 16: 5–40Google Scholar
  26. 26.
    Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50μg and fluticasone propionate 250μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34PubMedGoogle Scholar
  27. 27.
    Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105: 1108–6PubMedCrossRefGoogle Scholar
  28. 28.
    Fuller RW, Hallett C, Dahl R. Assessing equivalence of inhaled drugs. Respir Med 1995; 89: 525–7PubMedCrossRefGoogle Scholar
  29. 29.
    Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476–82PubMedCrossRefGoogle Scholar
  30. 30.
    Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998; 92 Suppl. A: 9–15PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • J. A. van Noord
    • 1
  • H. Lill
    • 2
  • T. Carrillo Diaz
    • 3
  • A. P. Greefhorst
    • 4
  • P. Davies
    • 5
  1. 1.Atrium HospitalHeerlenThe Netherlands
  2. 2.Tartu University Lung ClinicTartuEstonia
  3. 3.Servicio de AlergiaHospital de Gran Canaria Doctor NegrinLas Palmas de Gran CanariaSpain
  4. 4.GeerdinkswegHengeloThe Netherlands
  5. 5.Respiratory Therapeutic DevelopmentGlaxo Wellcome Research and DevelopmentUxbridgeEngland

Personalised recommendations